Identifying early-treatment risks and providing decision guidance to stay engaged in HIV care
Official title: Behavioral Risk Identification and Decision Guidance for Engagement
Run by Boston University · NCT07439003 · Data updated 2026-11-12
This project tests a retention toolkit to help adults in South Africa who are starting or re-starting HIV treatment stay engaged in care during their first six months.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15270 (estimated) |
| Sponsor | Boston University Academic / other |
| Locations | 1 site (Johannesburg, Gauteng) |
| Status | Recruiting |
| Started | March 27, 2026 |
| Main results expected | December 2026 |
| Study ends | December 2027 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07439003 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) who are starting or re-starting ART at a participating South African clinic and who can be contacted by mobile phone and consent to provide survey or interview data.
✕Probably not a fit
People outside the early treatment window, under 18, receiving care at nonparticipating clinics, or not reachable by phone are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Retain6 focuses on the high-risk first six months after ART initiation or re-initiation, combining quantitative surveys and qualitative interviews to map patient-level preferences, barriers, and facilitators of care. The project uses this data to identify behavioral risk factors for disengagement and to design a retention toolkit aimed at the early treatment period. Preliminary, real-world tests of toolkit components have been conducted at participating clinics in Johannesburg, with input from patients and clinic staff. Findings are intended to inform practical guideline changes and care models to reduce early losses from HIV care.
Why it matters
Potential benefit: If successful, the toolkit could reduce early ART interruptions, increase retention and viral suppression, and improve long-term health outcomes for people starting treatment.
How similar studies have gone: Previous retention-support interventions in sub-Saharan Africa have shown mixed but promising results, while focused toolkits specifically targeting the first six months are a newer approach with limited large-scale proof.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1: * ≥18 years old at treatment initiation or re-initiation * Initiating ART (newly or re-engaging after a period of interruption) or currently receiving ART at one of the participating study sites. Group 2: * Seeking care at an intervention site during their early treatment period * Reachable at telephone (mobile) number provided * Consented to participate in qualitative data collection Group 3: * Employed by DOH or an implementing partner at a study site * Trained and participated in delivering the intervention * Consented to participate in qualitative data collection Exclusion Criteria: No exclusion criteria for any group.
Where it's running
-
Health Economics and Epidemiology Research Office
Johannesburg, Gauteng, South Africa Recruiting
Study contacts
- Principal investigator: Sydney Rosen — Boston University
- Study coordinator: Linda Sande
- Email: lsande@heroza.org
- Phone: 27 63 115 1952
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Project SHIELD 2.0: Police Education to Support Public Health in Kentucky
Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.
-
New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV
This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.
-
Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV
This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.
-
HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters
This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.
-
Stigma-reducing program to help women who use drugs stay in HIV care
This test checks whether a stigma-reduction program helps women living with HIV who use drugs stay engaged in HIV care in Ukraine.
-
Platelets and HIV Reservoirs: A look at how platelets might harbor HIV in people living with HIV
This observational study tests whether HIV can be found inside platelets in adults with suppressed HIV on therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.